This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Olanzapine
Revision as of 23:07, 23 October 2017 by >Brack(motor control loss part of Extrapyramidal symptoms)
initial draft. This will contain a myriad of information and will be formatted later :) --Corticosteroid (talk) 22:58, 20 October 2017 (CEST)
Structure of olanzapine.A five milligram tablet of olanzapine manufactured by Apotex. This tablet is designed to dissolve in the mouth and be absorbed through the blood vessels inside of the mouth.
Olanzapine, first branded as Zyprexa, is a widely-used antipsychotic substance of the thienobenzodiazepine chemical class. It produces sedating and neuroleptic effects when administered. Olanzapine is known to cause weight gain and help induce Diabetes mellitus type 2 more frequently than other antipsychotics. On the other hand, it has less of a chance of producing tardive dyskinesia or an extrapyramidal reaction and also seems to treat schizophrenia very effectively.[1] Olanzapine can be given by mouth and can also be injected into a muscle. Telenzepine is another agent that shares the thienobenzodiazepine core structure. Olanzapine as useful as a trip aborter, especially for stimulants.
(doses:
Light: 2.5 mg
Medium: 5 to 7.5 mg
Heavy: 10 mg
Strong: 10 mg +)
Subjective effects
Physical effects
Hunger - This often happens over a course of treatment and not with one use.
Sedation - This effect is more often uncomfortably tiring than relaxing.
Cognitive euphoria - This effect is extremely rare. Olanzapine is often a dulling, "boring" pharmaceutical.
Cognitive dysphoria - This often includes an extreme sense of boredom or depression accompanied by uncomfortable sedation.
↑Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., ... & Kissling, W. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.
